Get started

Diagnostics

Perfect Setup: Thyrocare Cup and Handle | Long-Term WealthSTRONG BUY Setup 🏥 Entry: ₹1,490-1,510 (Current Level) Target 1: ₹1,557-1,570 Target 2: ₹1,611-1,630 Target 3: ₹1,665-1,685 Target 4: ₹1,750-1,800+ (Extended - Cup Depth Target) Stop Loss: ₹1,400 Technical Rationale: PERFECT CUP AND HANDLE PATTERN forming on Weekly Chart (educational diagram shown) Massive multi-year Cup formation (pink shaded area) from 2021 highs Handle consolidation currently forming near 1,400-1,500 range Strong +7.15% surge today breaking above handle resistance Volume at 2.82M - strong for weekly timeframe Price breaking above descending trendline (black line) Trading above both pink trendlines - bullish reversal confirmed RSI around 60-65 - healthy momentum with room for upside Healthcare/Diagnostics sector fundamentally strong Cup depth: ~1,500 to bottom (~400) = ~1,100 points Measured move: 1,500 base + 1,100 depth = 2,600 target (long-term) Multiple resistance levels: 1,557, 1,611, 1,665 Clear support at handle base: 1,400 Risk-Reward: EXCEPTIONAL 1:10+ ratio for full cup target Pattern: CUP AND HANDLE on WEEKLY Chart - one of the most powerful and reliable bullish continuation patterns in technical analysis Strategy: Long-term positional/investment (months to year+) Book 15% at T1 (1,565), 15% at T2 (1,620), 15% at T3 (1,675) Hold remaining 55% for major target 2,000-2,600 Trail SL to 1,500 after crossing T1 Key Levels: Handle Support (Critical): 1,400 - MUST HOLD Cup Rim Resistance: 1,500-1,520 (breaking now) Strong Resistance: 1,557, 1,611, 1,665 Extended Targets: 1,800, 2,000, 2,200-2,600 Major Support: 1,400, 1,350 Timeframe: WEEKLY chart - this is a MAJOR long-term investment setup (6-18 months) Cup & Handle Characteristics: ✅ Cup: Multi-year rounded bottom (2021-2024) - ✓ ✅ Handle: Consolidation at rim (current) - ✓ ✅ Volume: Decreasing in handle, increasing on breakout - ✓ ✅ Depth: Significant (1,100 points) - ✓ ✅ Breakout: Occurring now with volume - ✓ Volume Analysis: 2.82M weekly is substantial, confirming breakout authenticity Sector: Healthcare/Diagnostics - Thyrocare is major diagnostic chain, secular growth story Measured Move Calculation: Disclaimer: For educational purposes only. Not SEBI registered. Cup bottom: ~400 Cup rim: ~1,500 Depth: 1,100 points Target: 1,500 + 1,100 = 2,600 (100%+ upside potential) Conservative target: 1,800-2,000 (50-70% upside)
NSE:THYROCARELong
by rmhetre15
Swing Trading Setups: TWSTThis is a stock that went on my students' watchlists this week for potential swing trading. NASDAQ:TWST is coming out of a long-term down-trending correction and has completed the bottom. Accumulation ended and a HFT gap and run up followed on May 3rd. The stock retested the sideways trend highs which are now support for the current price. Pro traders are swing trading in these patterns. There are fewer wicks and tails and the stock has a very high Percentage of Shares Held by Institutions.
NASDAQ:TWST
by MarthaStokesCMT-TechniTrader
CEMI Chembio Diagnostics upside potentialChembio Diagnostics' analysts are forecasting revenues of US$54m in 2021, a substantial 56% improvement in sales compared to the last year. CEMI follows its bigger more profitable brother CODX in price action. Depending on the future development of the global pandemic, those stocks could grow rapidly. On 12/3/2020 Craig Hallum brokerage Upgraded the stock from Hold to Buy from $5.00 to $10.00 price target. Because of the offering, I've lowered my price target to 5.5usd. I`m looking forward to read your opinion about CEMI.
CLong
by TopgOptions
QUOTIENT LTD - NASDAQ: $QTNT Works On Its BaseFor the better part of 2019, the shares of QUOTIENT LTD - NASDAQ: QTNT have found themselves range-bound trading within the $8 - $11 zone, while seemingly continuing to build and work on its long drawn base as is evidenced in the Daily chart above. While further work is in order, QTNT remains in decent technical shape as the stock presently finds itself trading above all of its important moving averages 20/50/200 DMA's, which constitutes a healthy technical posture. Additionally, when extending out to both the Weekly and Monthly time-frames, one can also observe that QTNT remains in fine shape as well. Therefore, we have a favorable technical picture across multiple time-frames, which bodes well. Thus, while further work is required, both investors/traders may want to continue to monitor the action closely in the days/weeks ahead for further clues/evidence that things may be about to pick-up. In particular, should QTNT be capable of going topside of the $9.75 level, we may just witness a rapid re-test of the $11 level and perhaps a move into the $12 - $14 zone down the road.
Q
by OptionsGains
ENZO BIOCHEM INC - NYSE: $ENZ FlaggingLast week, ENZO BIOCHEM INC - NYSE:ENZ broke to higher ground and in the process, recaptured its 200 DMA out of a rounding bottom and now finds itself digesting/consolidating the move within a Flag pattern on lower volume as is evidenced in the Daily chart above. In addition, ENZ is now trading above all of its important moving averages 20/50/200 DMA's and finds itself in fine technical shape. Moving forward, both investors/traders may want to continue to monitor the action with a close eye. Specifically, should ENZ be capable of going topside of the $4.50 figure, such development would likely trigger its next advance with a primary objective in the $5-$6 zone with a secondary potential objective at $7 further down the road. Nevertheless, investors/traders may want to put ENZ front-and-center on their radars.
E
by OptionsGains
1
Photocure $PHO.OL stock rally ahead of Q4 report - One to watchPhotocure stock reacted with a heavy (overdone?) correction after the Q3 report, but has recovered nicely in later weeks. As mentioned in an earlier TradingView analysis ( ), NOK 36 and downwards presented a very good buying opportunity, which culminated when the correction bottomed at NOK 32,5 which was a very solid resistance upwards for a long time. Entry at these levels should probably be done with a keen eye on risk management and new investors may want to wait for the soon to come Q4 2018 report before making a move, but the long term uptrend looks promising, and at a valuation of only 113 million USD this Norwegian microcap could go a long way yet. Quoting Pengana capital about their position in Photocure: "Photocure has a current market capitalisation of USD $130 million and we estimate 2018 revenue of USD $25 million which is small compared to the potential US market opportunity valued at $1.3 billion. The company has also had great success in selling its product in Europe, with an 80% penetration in bladder surgery procedures in Scandinavia followed by 30% in Germany." www.raskmedia.com.au
OSL:PHO
by savepiginvest